The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
Key Financial Performance
Revenue from continuing operations Increased 6% year-over-year. This growth was mainly due to the greater number of franchise clinics in operation.
Consolidated adjusted EBITDA Increased 36% year-over-year. This improvement reflects the impact of work done on rightsizing costs, which helped offset a 1.5% decline in system-wide sales and negative comp sales of 2%.
System-wide sales Declined 1.5% year-over-year. This decline was attributed to lower new patient count.
Comp sales Decreased 2% year-over-year. The decline was due to lower new patient count.
Unrestricted cash and cash equivalents Remained strong at $29.7 million as of September 30, 2025. This reflects the company's financial stability.
Net income from continuing operations $290,000 or $0.02 per diluted share, compared to a loss of $414,000 or $0.03 per basic share in the same period last year. This improvement was mainly due to reduced impairment expenses related to refranchising.
Adjusted EBITDA from continuing operations Improved to $1.4 million compared to $262,000 in the same period last year. This reflects better cost management and operational efficiency.
Revenue for the 9 months ended September 30, 2025 Grew 6% to $39.7 million year-over-year. This growth was driven by an increase in the number of franchise clinics.
Consolidated net income for the 9 months ended September 30, 2025 Increased $7.7 million to $1.9 million year-over-year. This improvement was due to better cost management and operational efficiency.
Adjusted EBITDA from consolidated operations for the 9 months ended September 30, 2025 Expanded $1.3 million to $9.4 million year-over-year. This reflects improved operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Mobile App Enhancements: Launched the second release of the mobile app with new features like visit balance lookup, plan type, treatment progress, and patient experience surveys. Upcoming features include credit card updates and gamification.
Kickstart Plan: Introduced a new plan offering attractively priced adjustment packages (4, 8, or 12 adjustments) to help patients get rapid relief affordably. Approximately 25% of new patients are utilizing these packages.
National Marketing Campaign: Shifted marketing focus to pain relief and launched a national campaign, reallocating $500 per clinic per month from local to national advertising. This aims to drive stronger new patient demand and lead generation.
SEO and Microsite Improvements: Accelerated SEO initiatives and launched new localized clinic pages, resulting in a 20%-40% increase in organic search traffic for pilot clinics. Enhancements to Google business profiles and national website pages are also underway.
Refranchising Efforts: Entered an agreement to sell 45 corporate clinics in Southern California for $4.5 million. Actively negotiating terms for the remaining 33 corporate clinics.
Cost Structure Optimization: Reduced operating costs, leading to a 36% increase in consolidated adjusted EBITDA. G&A expenses decreased by 3%.
Transition to Pure-Play Franchisor: Continuing efforts to become a 100% franchisor by refranchising corporate clinics and implementing cost-saving measures.
Dynamic Revenue Management: Launched a pilot to test different pricing levels for wellness plans in diverse demographic areas to optimize revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic headwinds: The company is facing longer lead times in refranchising efforts due to lender-related dynamics, which could delay strategic initiatives and revenue generation.
Decline in system-wide sales and negative comp sales: System-wide sales declined by 1.5%, and comp sales were down 2%, indicating challenges in maintaining or growing revenue.
Lower new patient count: The company experienced a shortfall in new patient acquisition, which is critical for revenue growth and sustainability.
Marketing strategy risks: The shift from local to national marketing campaigns and the reallocation of franchisee advertising funds may take time to yield results, potentially impacting short-term revenue.
Clinic closures: The company closed 11 franchise clinics and 3 company-owned clinics in Q3, which could indicate operational or market challenges.
Attrition and patient retention: While patient attrition was on par with last year, it remains a concern for long-term revenue stability.
Refranchising uncertainties: The company is still negotiating terms for selling corporate clinics, and delays or unfavorable terms could impact financial performance.
Pricing sensitivity: The company is testing price increases in diverse demographic areas, which could risk alienating price-sensitive customers.
Supply chain and operational risks: Although not explicitly mentioned, the refranchising and clinic closures suggest potential operational inefficiencies or supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
System-wide sales: Expected to range from $530 million to $534 million for the full year 2025, revised from prior guidance of $530 million to $550 million.
Comp sales: Expected to be in the range of negative 1% to flat for 2025, revised from prior guidance of an increase in the low single-digit range.
Consolidated adjusted EBITDA: Maintained guidance to be in the range of $10.8 million to $11.8 million for 2025.
New clinic openings: Maintained guidance to be in the range of 30 to 35 for 2025.
2026 profitability: Continuing operations expected to be more profitable than 2025 due to refranchising efforts and realignment of corporate cost structure.
National marketing strategy: Shifted focus to pain relief with a new brand awareness campaign, 'Life, Unpaused,' and reallocation of $500 per clinic per month from local to national advertising.
Dynamic revenue management: Testing three-tiered pricing pilot for wellness plans to optimize revenue and profitability, with potential nationwide rollout based on results.
Patient-facing technology: Enhancements to the mobile app, including features like visit balance tracking, treatment plans, and gamification, aimed at improving patient experience and retention.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase: Since the last conference call in August, the company repurchased $5 million worth of stock. Additionally, the Board authorized an additional $12 million for the stock repurchase plan. During the third quarter, 228,000 shares were repurchased for $2.3 million, averaging approximately $10 per share. Since the quarter ended, an additional 312,000 shares were bought back for approximately $2.7 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the time frame for completing the refranchising of corporate clinics?
A:The company has an initial asset purchase agreement for 45 clinics in Southern California and is negotiating agreements for 33 other clinics. The timing is impacted by macroeconomic factors and lender dynamics, but the management is confident in making progress, though exact timing is hard to predict.
Q:What steps are being taken to turn around same-store sales or comps?
A:The company is piloting a pricing plan with three different price increase levels to determine the optimal price. They are also shifting external messaging to focus on pain, reallocating $500 per clinic per month from local to national marketing, and addressing changes in consumer search behaviors due to AI. Pricing is one of several levers being tested to improve comps.
Q:How does the company justify raising prices when comps are running slightly negative?
A:The company is testing price increases cautiously with three tiers to ensure consumer readiness. They are balancing affordability with market conditions and using pricing as one of several strategies, including marketing and technology investments, to drive positive comps.
Q:What initiatives are aimed at improving the breakeven point for new clinics?
A:The company is using a robust protocol to ensure new clinics open with higher sales volumes and ramp up faster. This includes generating a significant number of leads before opening through local community engagement and codifying best practices for clinic openings.
Q:What are the trends in comp growth during the quarter and post-quarter?
A:Comps were slightly softer at the end of the quarter compared to the average. The updated guidance reflects tougher comparisons in Q4 due to higher comps in the same period last year (4% in Q3 and 6% in Q4).
Q:What SG&A expense reductions are planned for next year?
A:The company is rightsizing its G&A structure post-refranchising, targeting reductions in salaries, wages, employee benefits, insurance, legal fees, and travel. Early signs of cost reductions are visible, but the bulk of the benefits will come as refranchising progresses. Detailed plans will be shared in the next earnings call.
Q:Is the company taking a blanket approach to raising prices or targeting specific packages and plans?
A:The company is testing price increases on recurring membership plans, which account for 80-85% of revenue. The test involves three price increase levels ($2 to $10) across 200 clinics in different geographies to determine the most appropriate pricing strategy.
Q:What is the general performance of the 45 units in Southern California being refranchised?
A:The 45 clinics in Southern California are generally good-performing units. The company is focused on finding strong operators to maintain and enhance their performance.
Q:Are franchise licenses being sold to existing franchisees or new ones?
A:The licenses are being sold to a mix of existing and new franchisees.
Q:What metrics are available for the new app's utilization and engagement?
A:The app has 178,000 downloads, and 18% of new patients are signing up through it. While it's too early to provide detailed metrics, initial feedback indicates a strong patient experience.
Q:Is the company planning to take pricing earlier than Q1 2026?
A:The company plans to implement pricing changes in Q1 2026 based on the results of the current pilot tests. If the tests require further adjustments, the timeline may shift, but Q1 2026 is the most likely scenario.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific timeline for completing the refranchising process, citing macroeconomic factors and lender dynamics. Additionally, they did not provide detailed metrics on app utilization and engagement, stating it was too early to share such data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO Bowman
Chief Marketing
Marketing Officer
SEO
Slide system
acquisition brand
advertising
area
asset purchase
audience
authority
care pain
change
consumer pain
cost structure
financials
fund
funnel
generation
goal
improvement
loss period
marketing effort
need
page
pain relief
patient count
period Slide
pilot
plan patient
protocol clinic
purchase agreement
refresh
security law
state
strategy
visibility
week
win
JYNT Transcript
The Joint Corp. (JYNT) Q1 2026 Earnings Call Transcript
Positive5-11
Despite the absence of operational and strategic updates, the financial performance shows a positive trend with revenue, net income, EBITDA, and operating margin all improving year-over-year. The company's ability to increase cash flow from operations further supports a positive outlook. The lack of concerning responses in the Q&A suggests no immediate risks were highlighted, which maintains the positive sentiment.
The Joint Corp. (JYNT) Q4 2025 Earnings Call Transcript
Unknown3-12
Despite positive full-year financial performance and optimistic marketing initiatives, the decline in comp sales and lack of specific metrics on attrition and new patient adds raise concerns. The cautious approach to pricing increases and the shift from local to national marketing may not yield immediate results. The Q&A revealed some positive signs, but uncertainties remain. Overall, the market may react neutrally over the next two weeks.
The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
The Joint Corp. (JYNT) Q2 2025 Earnings Call Transcript
Positive8-9
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
JYNT Slides
The Joint Q1 2026 slides: refranchising drives profitability surge2026-05-07
Joint Corp Q4 2025 slides: EBITDA rises 8% amid transformation push2026-03-12
The Joint Corp Q2 2025 slides: Refranchising accelerates as EBITDA jumps 52%2025-08-07
The Joint Corp Q1 2025 slides: Revenue grows 7% as franchise model expands2025-05-08
JYNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
